HMNC Brain Health raises $50M Series B to advance two depression drugs
read at Endpoints ↗DealNeutral
HMNC Brain Health announced it has closed a $50 million Series B financing round.
The capital will be used to move two depression drug candidates into mid-stage clinical trials.
The round was led by Medice, a family-owned German pharmaceutical company, with participation from other investors.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
read at Endpoints ↗85 words · retrieved Jun 15
comments(0)
5-min edit window · permanent after that